Navigation Links
BU researcher receives highest honor from the National Birth Defects Prevention Network
Date:2/27/2013

Boston, MAAllen A. Mitchell, MD, a professor of public health (epidemiology) and professor of pediatrics at the Boston University Schools of Public Health and Medicine, recently received the Godfrey P. Oakley, Jr., Award at the annual meeting of the National Birth Defects Prevention Network. Mitchell, who is also the director of Boston University's Slone Epidemiology Center (SEC), was recognized for his significant lifetime contributions to the field of birth defects.

Mitchell's interest in birth defects began as an undergraduate student and continued during his pediatric training. In 1967 he began work at the Boston Collaborative Drug Surveillance Program where he developed his focus on drug epidemiology (now called pharmacoepidemiology); among other activities, he worked on the analysis of Collaborative Perinatal Project data on birth defects and drugs in pregnancy.

In 1975 he joined the newly-created Drug Epidemiology Unit (now SEC) at Boston University, where following his interest in both pharmacoepidemiology and birth defects, Mitchell in 1975 applied the concept of case-control surveillance to the study of medications that may cause birth defects, and initiated the SEC Birth Defects Study (BDS) which continues to this time, having collected data on prenatal exposures for more than 40,000 malformed infants (and non-malformed infants) identified at multiple hospitals in the regions surrounding Boston, Philadelphia, Toronto, San Diego and most recently Nashville, as well as through birth defects registries in Massachusetts and New York state.

The BDS is now one of two data collection components collaborating with the American Academy of Allergy, Asthma, and Immunology in a national systematic surveillance effort (Vaccines and Medication in Pregnancy Safety Surveillance"VAMPSS") designed to evaluate the risks and safety of the wide range of medications taken by pregnant women. Mitchell also designed and directed epidemiologic efforts to evaluate pregnancy prevention efforts for drugs known to cause birth defects, including isotretinoin (Accutane and others) and thalidomide (Thalomid).

Mitchell is the author of numerous publications in the fields of birth defects pharmacoepidemiology and serves on many editorial boards and advisory committees. He obtained his undergraduate degree from Washington University in St. Louis in 1966 and his medical degree from Tufts University School of Medicine in Boston in 1970. He performed his pediatric residency training at the Boston Floating Hospital for Infants and Children (Tufts-New England Medical Center).

With this prestigious award the National Birth Defects Prevention Network honors Dr. Oakley who was instrumental in setting the birth defects agenda at the Centers for Disease Control and Prevention for many decades and in focusing national attention on the effects of folic acid in preventing neural tube defects.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
4. U of Alberta researcher steps closer to understand autoimmune diseases
5. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
6. UNH researchers find African farmers need better climate change data to improve farming practices
7. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
8. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
9. Researchers print live cells with a standard inkjet printer
10. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
11. Researchers reveal how a single gene mutation leads to uncontrolled obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
Breaking Biology News(10 mins):
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work ... agricultural industry. Pilot studies are about to get under way for the framework, which ... 5G innovations. The concept is expected to be transferred eventually to other industries that ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
Breaking Biology Technology: